Form 4: Semler Scientific CEO Douglas Murphy-Chutorian Reports Stock Option Grant
SEC Form 4 Filing
Douglas Murphy-Chutorian, CEO of Semler Scientific, Inc., reports the acquisition of stock options.
Summary
- On May 2, 2025, Douglas Murphy-Chutorian, the CEO of Semler Scientific, Inc., reported acquiring 25,000 stock options with an exercise price of $36.16.
- These options vest over four years, with 1/4 vesting on the first anniversary and the remaining 3/4 vesting monthly thereafter.
- The options expire on May 2, 2035.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a routine disclosure of executive compensation. The grant itself is a positive incentive for the CEO, but the filing is simply a required disclosure.
Positives
- The grant of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.
Industry Context
Stock option grants are a common practice in the technology and healthcare industries to incentivize executives and align their interests with shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in publicly traded companies, particularly in growth-oriented sectors like technology and healthcare.
- Companies like Medtronic, Boston Scientific, and Stryker also utilize stock options as part of their executive compensation plans.
- The vesting schedule of 1/4th after one year and then monthly thereafter is a typical vesting arrangement.
Stakeholder Impact
- The stock option grant incentivizes the CEO to improve company performance, potentially benefiting shareholders.
- Employees may view the grant as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 05/02/2025 | Date of the stock option grant and transaction. |
| 05/02/2026 | First vesting date for 1/4th of the stock options. |
| 05/02/2029 | Date when all stock options will be fully vested. |
| 05/02/2035 | Expiration date of the stock options. |
| 05/05/2025 | Date of signature for the Form 4 filing. |
Keywords
Semler Scientific, SMLR, stock options, Form 4, insider trading, Douglas Murphy-Chutorian, CEO, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.